HCPCS code J2357: Injection, Omalizumab, 5 mg

Acquire a list of the documentation and billing requirements needed to properly use and bill for HCPCS code J2357.

## **What is HCPCS code J2357?** HCPCS J code J2357 represents omalizumab (Xolair®) injection, 5 mg, an FDA-approved monoclonal antibody used in the treatment of several chronic allergic and inflammatory conditions. Omalizumab binds to human immunoglobulin E (IgE), preventing its interaction with high-affinity IgE receptors on mast cells and basophils, thereby inhibiting the allergic inflammatory cascade. The drug is primarily indicated for: - Moderate-to-severe persistent asthma in patients ≥6 years old with a positive skin test or in vitro reactivity to perennial aeroallergens, whose clinical features remain uncontrolled despite inhaled corticosteroid therapy. - Chronic spontaneous urticaria (CSU), previously referred to as chronic idiopathic urticaria (CIU), in patients ≥12 years old who remain symptomatic despite H1-antihistamine therapy. - Nasal polyps in adults with inadequate response to intranasal corticosteroids. Omalizumab is administered subcutaneously every 2–4 weeks, with dosing based on body weight and baseline IgE levels (for asthma). It is not intended to alleviate asthma exacerbations acutely or to treat of acute bronchospasm or status asthmaticus.

## **Documentation requirements** To support billing for J2357, documentation should include: - **Diagnosis**: The patient's diagnosis must prove medical necessity and align with an FDA-approved indication for omalizumab, such as allergic asthma, CSU, CRSwNP, or IgE-mediated food allergy. - **Clinical criteria**: Documentation should support that the patient meets specific clinical criteria, which often vary by payer and indication. For example, for allergic asthma, this may include: Patient age (e.g., 6 years or older for asthma). A positive skin test or in-vitro reactivity to a perennial aeroallergen. A pre-treatment serum IgE level within a specified range (e.g., 30 to 700 IU/mL for adults with asthma). A history of uncontrolled symptoms despite optimized use of other controller medications, such as high-dose inhaled corticosteroids. - **Treatment plan**: The record should detail the prescribed dose, frequency, and route of administration, along with the patient's weight. The dose is calculated based on the patient's weight and pre-treatment IgE levels. - **Administration**: Notes must confirm that the injection was performed by a qualified healthcare provider in a clinical or healthcare setting. - **Drug and procedure details**: Dose and frequency administered, along with lot number and manufacturer for drug tracking. This includes the route of administration. - **Lack of efficacy of other treatments**: Documentation should show that other, less complex treatments (e.g., antihistamines for CSU) were tried and failed or were not tolerated.

## **Billing requirements** When billing for J2357, it's crucial to follow these guidelines to avoid claim denials: - **Units**: Report J2357 per 5 mg of omalizumab administered. Calculate total units based on the cumulative dose (e.g., 150 mg of Xolair prefilled syringe injection = 30 units). - **Administration code**: J2357 is for the drug itself, not for its administration. You must also bill a separate CPT code for the injection procedure. Common correct codes include 96372 (Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular) or 96401 (Chemotherapy administration, subcutaneous or intramuscular, non-hormonal anti-neoplastic). Payer policies on which administration code to use can vary, so it's essential to check with the specific insurance carrier. - **Modifiers**: Depending on the situation and payer policy, modifiers may be necessary. For instance, the JW modifier (drug amount discarded/not administered to any patient) or JZ modifier (zero drug amount discarded/not administered to any patient) may be required to account for any wasted medication from a multi-dose vial. - **Prior authorization**: Many payers, including Medicare and commercial insurance plans, require prior authorization for omalizumab due to its high cost and specific usage criteria.

## **Other relevant codes** - **96372**: CPT: Injection, subcutaneous or intramuscular (administration code) - **J3590**: HCPCS: Unclassified biologics (used when coverage or coding for omalizumab was pending prior to J2357). - **J0179**: HCPCS: Injection, brolucizumab-dbll, 1 mg

Frequently asked questions

The dose and frequency of omalizumab are determined by the patient's body weight and their pre-treatment total serum IgE level, according to the manufacturer's dosing chart.

No. Omalizumab is strictly for chronic management of allergic conditions and is not indicated for acute bronchospasm or status asthmaticus.

Yes. Most Medicare Advantage and commercial insurers require prior authorization due to the high cost and specialty drug status of omalizumab.